20610-20-2

Usage

Uses

Used in Pharmaceutical Production:
2,3-Diaminopropionic acid methyl ester is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into complex organic molecules, contributing to the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 2,3-Diaminopropionic acid methyl ester is utilized as a building block for the creation of a wide range of organic compounds, highlighting its importance in the synthesis of various chemical entities.
Used in Medicinal Research:
2,3-Diaminopropionic acid methyl ester is used as a subject of research for its potential neuroprotective and anticonvulsant properties, indicating its value in advancing medical treatments for neurological conditions and seizure disorders.
Used in Chemical Industry:
2,3-Diaminopropionic acid methyl ester is also employed in the chemical industry for various applications, leveraging its unique chemical structure and reactivity in the production of specialty chemicals and materials.

Upstream product

• 67-56-1 methanol 
• 515-94-6 2,3-diaminopropanoic acid 
• 515-94-6 (S)-2,3-diaminopropionic acid 
• 1356449-88-1 calyxamide B 
• 1356449-87-0 calyxamide A 

Downstream Products

• 845728-82-7 C₂₀H₁₈N₂O₂ 
• 866632-67-9 1-(3'-bromobenzene)-3-carboxylpyrazinone 
• 1253792-30-1 C₁₁H₇BrN₂O₃ 
• 77087-60-6 3-(t-Butoxycarbonyl)amino-2-(RS)-aminopropionic acid methyl ester 
• 119140-63-5 2-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-4,5-dihydro-3H-imidazole-4-carboxylic acid methyl ester 
• 119140-64-6 2-[1-Benzyloxycarbonylamino-2-(4-benzyloxy-phenyl)-ethyl]-4,5-dihydro-3H-imidazole-4-carboxylic acid methyl ester 
• 728872-66-0 methyl (2S)-3-amino-2-({[4-(phenylethynyl)phenyl]carbonyl}amino)propanoate 
• 119140-50-0 2-(Benzyloxycarbonylamino-methyl)-4,5-dihydro-3H-imidazole-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH

The present invention relates to glucose-responsive insulin analogues, compositions including the glucose-responsive insulin analogues, and methods of lowering blood sugar of a patient using the insulin analogue or compositions thereof.

Lipodiscamides A-C, new cytotoxic lipopeptides from discodermia kiiensis

Lipodiscamides A-C, three new lipodepsipeptides, were characterized from the marine sponge Discodermia kiiensis. These structurally rare cyclic lipodepsipeptides were found to possess an unprecedented dilactone macrocycle and, thus, represent a new family of lipopeptides. They are the only lipopeptides bearing 4S-hydroxy-trans-2-enoate, and noncanonical amino acids, l-3-ureidoalanine (Uda), E-dehydronorvaline (Denor), and d-citrulline (Cit). MTT assays against P388 and HeLa cells revealed the moderate cytotoxicity of all three compounds.

Calyxamides A and B, cytotoxic cyclic peptides from the marine sponge Discodermia calyx

Cyclic peptides containing 5-hydroxytryptophan and thiazole moieties were isolated from the marine sponge Discodermia calyx collected near Shikine-jima Island, Japan. The structures of calyxamides A (1) and B (2), including the absolute configurations of all amino acids, were elucidated by spectroscopic analyses and degradation experiments. The structures are similar to keramamides F and G, previously isolated from Theonella sp. The analysis of the 16S rDNA sequences obtained from the metagenomic DNA of D. calyx revealed the presence of Candidatus Entotheonella sp., an unculturable δ-proteobacterium inhabiting the Theonella genus and implicated in the biosynthesis of bioactive peptides.

Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series

Structure-activity relationships for a series of pyrazine carboxamide CB1 antagonists are reported. Pharmaceutical properties of the series are improved via inclusion of hydroxyl-containing sidechains. This structural modification sufficiently improved ADME properties of an orally inactive series such that food intake reduction was achieved in rat feeding models. Compound 35 elicits a 46% reduction in food intake in ad libidum fed rats 4-h post-dose.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.